REG - BioPharma Credit PLC - Result of General Meeting

Biopharma CreditAnnouncement

28/12/2023 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231228:nRSb0859Ya&default-theme=true

RNS Number : 0859Y  BioPharma Credit PLC  28 December 2023

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF GENERAL MEETING

 

The Company is pleased to announce that, at the General Meeting held today,
the resolution put to the meeting was passed by way of a poll.

 

 

 Resolution                                                               Votes        %      Votes Against  %     Votes Withheld(1)

                                                                          For
 To approve the continuation of the Company's business as a closed-ended  704,196,309  94.06  44,493,800     5.94  21,716
 investment trust.

 

1.     A 'vote withheld' is not a vote under English law and is not
counted in the calculation of votes 'for' or 'against' a resolution.

 

A copy of the resolution has been submitted to the National Storage Mechanism
and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

28 December 2023

 

 

Enquiries

 

BioPharma Credit plc

 

via Link Company Matters Limited

 

Company Secretary

 

T. +44 (0) 333 300 1950

 

Buchanan

 

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

 

+44 (0) 20 7466 5000

 

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFVLFLXLLBFBX